Laboratory Biomarkers for Diagnosis and Prognosis in COVID-19

Frontiers in Immunology

Patricia R. M. Rocco³  Denise Battaglini⁴  Paolo Pelosi⁵  Hugo C. Castro-Faria-Neto⁶  Miquéias Lopes-Pacheco⁷ 

[1] Anesthesia and Intensive Care, San Martino Policlinico Hospital, Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) for Oncology and Neuroscience, Genoa, Italy;COVID-19 Virus Network from Brazilian Council for Scientific and Technological Development, Brasília, Brazil;COVID-19 Virus Network from Foundation Carlos Chagas Filho Research Support of the State of Rio de Janeiro, Rio de Janeiro, Brazil;Department of Medicine, University of Barcelona, Barcelona, Spain;Department of Surgical Science and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy;Laboratory of Immunopharmacology, Oswaldo Cruz Institute - Fiocruz, Rio de Janeiro, Brazil;Laboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil;

关键词: biomarkers;    COVID-19;    inflammation;    metabolomics;    proteomics;   

DOI  :  10.3389/fimmu.2022.857573

来源: DOAJ

【 摘 要 】

Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) causes a wide spectrum of clinical manifestations, with progression to multiorgan failure in the most severe cases. Several biomarkers can be altered in coronavirus disease 2019 (COVID-19), and they can be associated with diagnosis, prognosis, and outcomes. The most used biomarkers in COVID-19 include several proinflammatory cytokines, neuron-specific enolase (NSE), lactate dehydrogenase (LDH), aspartate transaminase (AST), neutrophil count, neutrophils-to-lymphocytes ratio, troponins, creatine kinase (MB), myoglobin, D-dimer, brain natriuretic peptide (BNP), and its N-terminal pro-hormone (NT-proBNP). Some of these biomarkers can be readily used to predict disease severity, hospitalization, intensive care unit (ICU) admission, and mortality, while others, such as metabolomic and proteomic analysis, have not yet translated to clinical practice. This narrative review aims to identify laboratory biomarkers that have shown significant diagnostic and prognostic value for risk stratification in COVID-19 and discuss the possible clinical application of novel analytic strategies, like metabolomics and proteomics. Future research should focus on identifying a limited but essential number of laboratory biomarkers to easily predict prognosis and outcome in severe COVID-19.

【 授权许可】

Unknown